Nouscom receives approval to begin Phase 1b trials of NOUS-PEV, a novel personalized cancer immunotherapy

Results from preclinical proof-of-concept studies (published in Nature Communications[2]) demonstrated that a single administration of the GAd vaccine incorporating many neoantigens can eradicate large tumors when combined with checkpoint inhibition such as anti-PD1 or anti-PD-L1 treatment and triples the efficacy of such checkpoint inhibitors. The preclinical results also demonstrated strong and broad CD8+ and CD4+ neoantigen-specific T cell responses following vaccination, which are known to be indicative of a clinical anti-tumor effect.

BASEL, Switzerland, 11/03/2021 (informazione.news - comunicati stampa - scienza e tecnologia)

Results from preclinical proof-of-concept studies (published in ) demonstrated that a single administration of the GAd vaccine incorporating many neoantigens can eradicate large tumors when combined with checkpoint inhibition such as anti-PD1 or anti-PD-L1 treatment and triples the efficacy of such checkpoint inhibitors. The preclinical results also demonstrated strong and broad CD8+ and CD4+ neoantigen-specific T cell responses following vaccination, which are known to be indicative of a clinical anti-tumor effect.

The new Phase 1b trial will evaluate the safety, feasibility, and preliminary efficacy per RESIST 1.1 criteria of NOUS-PEV in combination with the anti-PD-1 checkpoint inhibitor pembrolizumab in 28 patients with either locally advanced 1L melanoma or 1L NSCLC expressing more than 50% PD-L1. This multicenter trial will be conducted in Spain and other European countries.

, said: "

, said: "

accine ncoded eoAg nrestricted election (VENUS)

A.M. D'Alise et al. Nature Communications 2019

Nouscom is a privately held oncology company developing next-generation immunotherapies. Nouscom's proprietary technology platform harnesses the full power of the immune response by combining viral vectored vaccines based on neoantigens with other immunomodulators.

Nouscom is currently advancing the clinical development of its programs:

Nouscom is led by an experienced management team with deep roots in the pharma and biotech industry (Merck, Novartis, Lilly, Johnson and Johnson, Incyte and Okairos (acquired by GSK)), and are veterans in the field of viral vectored vaccines.

Nouscom, which was founded in 2015 and is headquartered in Basel, Switzerland with operations in Rome, Italy , is backed by international life sciences investors: 5AM , Abingworth, LSP (Life Sciences Partners) and Versant Ventures.

For more information on Nouscom, please visit the company's website at www.nouscom.com

E : info@nouscom.com

T : +41 61 201 1835

E : nouscom@citigatedewerogerson.com

T : +44 (0)20 7638 9571